Sipuleucel-T (Provenge) injection the first immunotherapy agent (Vaccine) for hormone-refractory prostate cancer

P and T

Volumn 36, Issue 4, 2011, Pages 197-202

  Anassi, Enock ^a   Ndefo, Uche Anadu ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIGEN; DIPHENHYDRAMINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PARACETAMOL; PLACEBO; POLYURETHAN; PROSTATE SPECIFIC ANTIGEN; PROVENGE; RINGER LACTATE SOLUTION; TUMOR NECROSIS FACTOR ALPHA;

ANDROGEN INDEPENDENT PROSTATE CANCER; ANEMIA; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; B LYMPHOCYTE; BACKACHE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELLULAR IMMUNITY; CEREBROVASCULAR DISEASE; CHILL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PACKAGING; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEVER; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HAIR LOSS; HEALTH CARE COST; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; IMMUNE RESPONSE; INFECTION; INFECTION CONTROL; INFLUENZA; LEUKAPHERESIS; LIMB PAIN; LYMPHOCYTE ACTIVATION; MACROPHAGE; MEDICAID; MULTIPLE CYCLE TREATMENT; MUSCLE FATIGUE; MYALGIA; MYASTHENIA GRAVIS; MYOSITIS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ORAL PARESTHESIA; PAIN; PARESTHESIA; PATIENT INFORMATION; PHAGOCYTOSIS; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RHABDOMYOLYSIS; RISK REDUCTION; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; TUMOR FLARE; UPREGULATION; VOMITING;

EID: 79955719446     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59: 225-249.
2. Fauci AS, Kasper DL, Braunwald E, et al. (eds). Harrison's Principles of Internal Medicine, 17th ed. New York: McGraw-Hill; 2008:594-600.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitox - an trone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351: 1502-1512.
4. Ross RW, Kantoff PW. Hormone-refractory prostate cancer: Choosing the appropriate treatment option. Oncology (Williston Park) 2007;21:185-193.
5. Newling DW, Dennis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer: An - alysis of the criteria for evaluation used in the European Organization for Research and Treatment of Cancer. Genitourinary Group Study, 30853. Cancer (Phila) 1993; 72:3793-3798.
6. Bok RA. Treatment of prostate cancer: Therapeutic potential of targeted immunotherapy with APC8015: Therapeutics and clinical risk management. 2008; 4(1):79-85.
7. Burch PA, Breen JK, Buckner JC, et al. 2000. Priming tissue-specific C cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175-2182.
8. Patel PH, Kockler DR. Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008;42(1):91-98.
9. Risk M, Corman JM. The role of immunotherapy in prostate cancer: An overview of current approaches in development. Rev Urol 2009;11(1):17-27.
10. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous, dendritic cells pulsed with HLA-A0201-specific peptides from prostate specific membrane antigen. Prostate 1996;29:371-380.
11. Understanding Cancer Series: The Immune System. National Cancer Institute. Available at: www.cancer.gov/cancertopics/understandingcancer/immunesystem/Page34. Accessed February 25, 2011.
12. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-3903.
13. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory pros - tate cancer. J Clin Oncol 2006;24:3089-3094.
14. Higano CS, Schellhammer PF, Eric J, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-3679.
15. Provenge (sipuleucel-T) suspension for intravenous infusion, prescribing information. Seattle, Wash.: Dendreon Corp.; 2010. Available at: www.dendreon.com/ prescribing-information.pdf. Accessed November 15, 2010.
16. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Pro - venge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent pros - tate cancer: A phase 2 trial. Prostate 2004; 60:197-204.
17. Antonarakis ES, Drake CG. Current status of immunological therapies for pros tate cancer. Curr Opin Urol 2010; 20(3):241-246.
18. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration- resistant prostate cancer. N Engl J Med 2010;363:411-422.
19. Force R, Pugmire B, Culbertson V, et al. A taxane total cost of care analysis in metastatic breast cancer: Results of private payor claims data (Abstract 1076). Cancer Res 2009;69(24 Suppl 3), December 15, 2009, online.
20. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-245.
21. Miller D. Dendreon's Provenge costs the same as chemotherapy. Minyanville Media, July 29, 2010. Available at: www.minyanville.com/businessmarkets/articles/dendreon-provenge-cost-taxoteresanofi-aventis/7/29/2010/id/29371. Accessed November 5, 2010.
22. Mulkhy N. Medicare already paying for Provenge for some patients: National coverage analysis still important. Medscape Medical News, January 6, 2011. Available at: www.medscape.com/viewarticle/735366. Accessed February 2, 2011.